Call for Independent Medical Education (IME) Grant Notification: Medical Affairs, Knowledge Exchange
|
|
- Geoffrey Holt
- 5 years ago
- Views:
Transcription
1 DATE of issue: October 1, 2018 Call for Independent Medical Education (IME) Grant Notification: Medical Affairs, Knowledge Exchange Therapeutic Area and Disease: Breast Cancer The Medical Affairs Team at Roche Canada invites members of the medical educational provider community to submit applications for IME grants subject to the terms described below. This Call for IME provides public notice of the availability of funds in a general topic area for activities where recognized scientific or educational needs exist and funding is available. Purpose: As part of its scientific mission, Roche supports grants for IME as a means to enhance the medical community's ability to care for patients. This mission is achieved by supporting quality independent education that addresses evidence-based, valid educational gaps in accordance with the Royal College of Physicians and Surgeons of Canada CPD MOC Program and the spirit of the prevailing Innovative Medicines Canada s guidance. Eligibility Criteria: Appendix A Geographical Scope: Canada (if a Provincial, Territorial or Regional specific proposal is submitted, please include how needs were determined and how the proposed activity will address these needs). Submission Instructions: Providers who meet the eligibility criteria and are interested in submitting a response to this Call for IME may submit their grant request using the Roche grant application form: Appendix B can be accessed at LINK TO FORM Deadline for Submission of Applications: November 12, 2018 (09:00 EST) Award Decision Date/Mechanism: Final approvals and denials of successful applicants will be communicated through no later than November 26, There have been no predetermined approvals. All submissions will be reviewed equally. IME providers should only respond to this Call for Grant if they have read and understand the terms, purpose, therapeutic landscape and educational request identified below. Applicants will be expected to identify independent clinical knowledge gaps that are clinically accurate, relevant and aligned to this Call for IME Grant, which can be referenced. Call for IME Grant Area of Interest Available Funding Metastatic Triple Negative Breast Cancer Roche has a budget of up to $75,000 CDN available for the activity or program (single or multiple linked activities, including live events and/or online education programs and/or accredited printed pieces, intended to address the identified 1/10
2 unmet educational needs for the target audience outlined in this Call for Grant Notification (CGN). Budget submissions should be broken down per activity if more than one approach is proposed. Educational providers may request up to a maximum of $75,000 CDN but are not required to design an IME that utilizes the full available amount. If Provincial, Territorial or Regional specific proposal is submitted, ensure requested funds are reflective of the audience reach. Background Context Triple-negative breast cancer (TNBC), which is characterized by the lack of expression and/or amplification of the targetable receptors for estrogen, progesterone and human growth factor receptor 2 (HER2), accounts for 15% to 20% of all breast cancers 1-3. This breast cancer subtype is an aggressive, heterogeneous disease with high unmet need. Patients with TNBC experience poor clinical outcomes, including earlier and higher relapse rates, compared with other breast cancer subtypes 4-6. In patients that relapse or experience metastatic disease, there is no cure 7. Chemotherapy is the mainstay systemic treatment for TNBC in all settings, and the use of taxanes as first-line treatment for advanced disease is supported by international guidelines, including those of the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) For patients with metastatic disease, there is a significant unmet medical need due to limited treatment options and short survival after chemotherapy failure 12. Two promising avenues of clinical research in metastatic TNBC are targeted therapies and immunotherapies, including checkpoint inhibitors Educational needs Immunotherapy is an emerging therapeutic approach, which has changed the treatment landscape for many types of cancers, including lung and melanoma 15,16. The immunogenicity characteristics of TNBC, coupled with its high unmet need, make it a potential target for immunotherapy Given the emerging evidence to support the use of immunotherapy in metastatic TNBC 14, there is a need for education to enhance physician knowledge and understanding around these latest advances. According to a recent needs assessment 23, topics related to TNBC were the most compelling, along with novel emerging therapies, including cancer immunotherapies. Medical oncologists also indicated a lack of familiarity relating to the roles of PD-L1 and immunogenicity of breast cancer. This call for an independent medical education grant is specific for metastatic TNBC, which has 2/10
3 the greatest unmet need, as there is no cure and the 5-year overall survival of patients with TNBC metastatic disease is only 11.2% 24. In order to fully embrace the potential of cancer immunotherapies in metastatic TNBC, healthcare providers need sufficient knowledge to be confident using these treatments in clinical practice. Thus, key topics of interest relating to metastatic TNBC include: Disease overview, including current treatment recommendations and the remaining unmet need New and emerging immunotherapy options (including PD-1/PD-L1 inhibitors) and their associated biomarkers How biomarker testing may identify which patients most likely benefit from immunotherapies Safety profile of emerging immunotherapies compared with the current standard of care Ideally, a broad overview of these topics should be covered in the educational activity (or activities). Methods Measures Results Roche is seeking to support an education grant that: 1. Supports clinicians' information and learning needs as outlined, but not limited to, those outlined above. 2. Identifies further clinician baseline knowledge and awareness needs, together with competence gaps. 3. Provides fair and balanced educational initiatives that translate into benefits for patients, their caregivers and healthcare providers. 4. Is aimed at the identified areas and that embraces effective models for delivery and scientific exchange. Roche believes that on the basis of external research that this educational initiative would benefit, but not be limited to Medical Oncologists and Molecular or Clinical Pathologists and the program(s) must be accredited for physicians according to Royal College of Physicians and Surgeons of Canada CPD MOC Program. Roche encourages IME providers to submit grant requests that address specific clinician knowledge, competence, and performance gaps. Consideration will be given to those grant requests intended to demonstrate how the educational initiative(s) would improve patient care by closing gaps and assessing healthcare providers behaviour relative to standards of care and best available evidence. The educational initiative should provide the participants with the latest data to help with the evaluation and utilization of evidence that leads to appropriate decision- 3/10
4 making and enhancement of patient care. The educational provider should therefore show that learners: 1. Have demonstrated understanding of the educational activity; 2. Have demonstrated competence improvement as a result; 3. Will use evidence-based concepts to consider changing behaviour where appropriate or relevant. Discussion Roche encourages IME provider(s) who are awarded approval to: 1. Consider whether or not the educational intervention(s) reduced on average the time taken for the educational audience to adopt information, demonstrating how this was achieved; 2. Demonstrate key findings via outcomes analysis (see Measures and Results sections above); 3. Summarize (through written analysis) their understanding of the outcomes metrics, identifying the association between the intervention and outcomes; 4. Identify any further knowledge gaps and unanticipated barriers and/or activity/outcomes limitations; explain the reason(s) for them, and describe the efforts made to address them as necessary. Additional Considerations All grant submissions should describe how the educational provider plans to determine the extent to which the initiatives have met the stated objectives and closed the identified clinical/educational gap(s) including the qualifications of those involved in the design and analysis of the outcomes. The successful grant recipient will, upon completion of the activity (or activities), be asked to provide documentation attesting to how the funds were used, and must return any unused funds to Roche, along with the requisite activity outcomes/impact report. Terms and Conditions 1. All grant applications received in response to this Call for IME will be reviewed in accordance with all Roche policies. 2. This Call for IME Grant does not commit Roche to award a grant or to pay any costs incurred in the preparation of a response to this request. 3. Roche reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this Call for IME Grant. 4. For compliance reasons, and in fairness to all education providers, all communications about this Call for IME Grant must come exclusively to mississauga.ime_grant@roche.com 5. Failure to follow any instruction within this Call for IME Grant may result in a denial. Transparency 4/10
5 As a matter of corporate responsibility, Roche reserves the right to publicly disclose, for example via reports published on its website, financial support provided in the form of grants or other contributions to third-party organizations. In such case Roche will report information such as the name of the grantee, a brief description of the program/project, and the amount of the grant award. References 1. Kohler BA, et al. J Natl Cancer Institute (2015); 107(6):djv Wolff AC et al. J Clin Oncol (2013); 31(31): Hammond ME et al. J Clin Oncol (2010); 28(16): denbrok WD et al. Breast Cancer Res Treat (2017); 161: Malorni L et al. Breast Cancer Res Treat (2012); 136(3): Dent R et al. Breast Cancer Res Treat (2009): 115: Egger SJ et al. Cochrane Database of Systematic Reviews 2017, Issue Senkus E et al. Ann Oncol (2015); 26 (Supplement 5):v8-v30 9. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Breast Cancer. Volume March 20, Denduluri N et al. J Clin Oncol (2016); 34(20): Cardoso F et al. Ann Oncol (2017); 28: Bajaj P et al. Ann Oncol (2017); 28(5): mdx Targeted therapies in Phase III development for TNBC include: (a) the AKT inhibitor ipatasertib in combination with chemotherapy as first-line treatment for mtnbc (ClinicalTrials.gov ID, NCT ); (b) the PARP inhibitor talazoparib for BRCA-mutant advanced breast cancer (ClinicalTrials.gov, NCT ); (c) the antibody drug conjugate sacituzumab govitecan for relapsed or refractory TNBC (ClinicalTrials.gov ID, NCT ), which was granted US FDA Fast Track designation for treatment of patients with TNBC; and (d) bicalutamide for treatment of androgen receptor positive mtnbc (ClinicalTrials.gov ID, NCT ). 14. Immunotherapy agents in Phase III development for TNBC include the checkpoint inhibitors TECENTRIQ and pembrolizumab as monotherapy and in combination with chemotherapy for early and advanced TNBC (ClinicalTrials.gov IDs, NCT , NCT , NCT and NCT ), avelumab monotherapy for high-risk early TNBC (ClinicalTrials.gov ID, NCT ) and the tumour endothelial targeting agent EndoTAG-1 with chemotherapy as first-line treatment for visceral mtnbc (ClinicalTrials.gov ID, NCT ). 15. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Non-small cell lung cancer. Version Dummer R et al. Ann Oncol (2015); 26(Supplement 5):v Wang, Y et al. Nature (2014); 512: Lehmann, BD et al. J Clin Invest (2011) Jul;121(7): Cimino-Mathews, A et al. Hum Pathol (2013); Oct;44(10): Loi, S et al. Ann Oncol (2014); 2014 Aug;25(8): Chen DS and Mellman I. Immunity (2013); Jul 25;39(1): Mittendorf, EA et al. Cancer Immunol Res 2014; Apr;2(4): /10
6 23. Assessing the knowledge gap in breast cancer: A medical knowledge gap evaluation created for Roche in December Howlader N et al., Cancer Epidemiol Biomarkers Prev Jun;27(6): /10
7 Appendix A Eligibility Criteria for Independent Medical Education (IME) Grant Recipients Roche Grant for Independent Medical Education (IME) to Healthcare-Related Entities can only be provided for the purpose of supporting healthcare-related education and must always ultimately benefit patients and/or public health. IME is generally defined as a healthcare-related educational activity for HCPs initiated and organized independently from Roche by an IME Provider such as a hospital, academic center, society or association, or medical education company, and where Roche has no influence on the content of the program. The IME Provider must be an independent third party that has full control over the development and selection of all aspects of the activity, including content, presenters, moderators and audience. Roche is not providing Grants for IME to the following: 1. Individual HCPs or individual patients or organisations owned or controlled by individual HCPs 2. Small business associations of HCPs, e.g. private physician offices, private group practices, small private hospitals (comprising, as a general rule, less than 10 HCPs) 3. Not-for-profit foundations formed by a small number of HCPs (as a general rule less than 50 HCPs) In order to be eligible, the funding must not be used: 1. To improperly induce or to reward the prescription, recommendation, purchase, order, supply, use, administration, sale or lease of a Roche Product or Service; 2. For the purpose of Pre-approval or Off-label Promotion of a Roche Product; 3. To inappropriately influence regulatory, pricing, formulary or reimbursement decisions; 4. To influence the content of Clinical Practice Guidelines; 5. For relationship building purposes. 6. For standalone entertainment or social events Firewall requirements for IME Providers The IME Provider must be an independent third party that does not provide strategic and promotional or marketing related services to Roche or the IME Provider must certify that a proper firewall exists between the related promotional and IME services. Provision for an independent activity or event specific Grant 1. Grants are provided for a specific activity or event that may not be organized nor influenced in any way by Roche. Additionally, Roche cannot receive any direct benefit in return when providing a Grant. 2. The specific activity or event must be described in the application form link and the description must be sufficiently complete in order for Roche to be able to evaluate whether or not to provide the support. a. It should usually contain at least the following information: 7/10
8 i. Background of the request including objectives and expected result of the event / activity ii. Description of why the event / activity is necessary (unmet educational need) iii. Intended audience of the event / activity iv. Whether or not other companies have been invited to support the event / activity v. In case of live event additionally: Proposed agenda and description of the planned location. vi. Requested amount of support, including cost breakdown for event / activity; 3. Grant requests that contain unacceptable budget line items will be ineligible such as: a. Funding for healthcare professional partners or guests. b. Faculty lodging and/or expense reimbursement out of proportion with the number of days that the faculty is presenting c. Gifts/prizes for faculty or attendees d. Request for food only e. Funding for faculty dinners not related to content review f. Honoraria or costs not according to Fair Market value FMV and the applicable local laws, regulations and industry codes, in the country where the attending HCP has his/her primary practice g. Lavish venues and venues that detract from the educational activity as the primary purpose. 4. Grants are provided for a fixed period of time and cannot be self-renewing General 1. The organization will provide an official receipt and full cost reconciliation upon request that meets applicable accounting standards. 2. If a Grant is approved, the organization must enter into a written agreement with Roche Appendix B Roche Grant Application Form (Google form) LINK NOTE: This form must be submitted in its entirety by November 12 th, 2018 All communications about this Call for IME must be directed exclusively to mississauga.ime_grant@roche.com 1) Address 2) Name (given, surname) Provide your first and last name. 3) IME Provider Name Provide the name of your organization. 8/10
9 4) Background Provide a summary of the educational need, which should include: (1) the nature and severity of the clinical gap in the specifically identified area, and (2) a summary of the baseline knowledge / competence / performance gaps for the potential grant's identified educational audience(s). 5) Methods Provide a brief and concise description of the educational initiative, including all educational formats / interventions recommended for the potential grant submission. 6) Measures Provide a brief description of the tools and/or strategies for measuring the educational impact that will be incorporated into the proposed grant. 7) Results Provide a brief and concise description of any knowledge, competence, and/or performance changes expected for the learner after participating in this education. 8) Will the activity (activities) be accredited? The activity must be accredited. Provide name of accrediting body. Proposed activities within Grant application must be reviewed and approved for accreditation in accordance with the Maintenance of Certification (MOC) Program by the Royal College of Physicians and Surgeon of Canada. 9) Will you be working with a third party to develop/accredit the activity (activities)? Provide name of third party below Additional Information: Submit additional supporting documentation and details of the proposal to mississauga.ime_grant@roche.com Type of activity: face-to-face [live or virtual event(s)] /online activity /accredited printed piece/ blended learning curriculum Activity start date Intended audience of the event/activity (activities), anticipated number of participants If Provincial, Territorial or Regional specific proposal is submitted, please include how regional needs were determined and how activity will address. 9/10
10 Requested amount of support, including a detailed cost and resource breakdown (e.g. content development, logistics, distribution, number of IME Provider staff involved, pass through costs etc.) for the event/activity Whether or not the IME Provider has been in contact with other companies to support/sponsor the same event/activity 10/10
Issue Date: 8 July Call for Independent Medical Education (IME) Notification: Roche Scientific Communications
Call for Independent Medical Education (IME) Notification: Roche Scientific Communications Therapeutic Area and Disease: Hematology Lymphoma The Global Medical Affairs Hematology Team at Roche invites
More informationPfizer Independent Grants for Learning & Change Request for Proposals (RFP) Rheumatoid Arthritis Mono- and Combination DMARD Therapy in RA Patients
Pfizer Independent Grants for Learning & Change Request for Proposals (RFP) Rheumatoid Arthritis Mono- and Combination DMARD Therapy in RA Patients I. Background The mission of Pfizer Independent Grants
More informationBristol-Myers Squibb Independent Medical Education
Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date 6/15/18 RFE Requestor Information RFE Code Name: Pavit Singh, PharmD Title: Post-Doctoral Fellow, Independent
More informationEHR Developer Code of Conduct Frequently Asked Questions
EHR Developer Code of Conduct Frequently Asked Questions General What is the purpose of the EHR Developer Code of Conduct? EHR Association (the Association) members have a long tradition of working with
More informationBristol-Myers Squibb Independent Medical Education
Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date August 10, 2017 RFE Requestor Information RFE Code Name: Maria Deutsch, MS, PharmD, RPh Title: IME Specialist,
More informationNovo Nordisk Pharma AG Methodology Note - reporting year 2016 ( Methodology )
Novo Nordisk Pharma AG Methodology Note - reporting year 2016 ( Methodology ) Table of contents Preamble... 0 1. General Summary... 1 2. Terminology and Definitions... 2 3. Change log... 8 Preamble Novo
More informationBristol-Myers Squibb. Request for Educational Activity (RFE)
Bristol-Myers Squibb Independent Medical Education Request for Educational Activity (RFE) Date RFP Code Therapeutic Area Areas of Interest Educational Design Intended Audience Budget Accreditation Geographic
More informationNCCN/Eli Lilly and Company Quality of Care in Gastric Cancer Request for Proposals (RFP)
I. Introduction NCCN/Eli Lilly and Company Quality of Care in Gastric Cancer Request for Proposals (RFP) National Comprehensive Cancer Network (NCCN ) and Eli Lilly and Company (Lilly) are collaborating
More informationII. Requirements Date RFP Issued: 07/11/2013 Use of Patient-Reported Outcome Measures in Management of Rheumatoid Arthritis (RA) I.
Pfizer Independent Grants for Learning & Change Request for Proposals (RFP) Rheumatoid Arthritis Patient-Reported Outcome Measures in Management of Rheumatoid Arthritis I. Background The mission of Pfizer
More informationInformation Technology Solutions
Information Technology Solutions World Institute of Pain (WIP) Excellence in Pain Practice Award Award Applicant Site Inspection Handbook June 28, 2010 WIP EPP Award Site Inspection Handbook Page 2 Table
More informationSeed Grant Guidelines
Seed Grant Guidelines Never doubt that a small group of thoughtful committed citizens can change the world; indeed, it's the only thing that ever has. Margaret Mead. Contents Background...3 About the BC
More informationIntroducing NCCN Academy for Excellence & Leadership in Oncology April Program Overview
Introducing NCCN Academy for Excellence & Leadership in Oncology April 2009 Program Overview In 2009, NCCN will launch the NCCN Academy for Excellence & Leadership in Oncology, a series of oncology certificate
More information4. Project Inform does receive restricted donations from corporations, non-profits, foundations, and government entities.
DONATION GUIDELINES As a non-profit organization, Project Inform is able to fulfill its mission and provide services, free of charge, because of its fundraising and outreach efforts. Project Inform receives
More informationRxVACCINATE: A National Education and Practice Support Initiative to Increase Pharmacist Administered Pneumococcal Vaccinations.
RxVACCINATE: A National Education and Practice Support Initiative to Increase Pharmacist Administered Pneumococcal Vaccinations. Pfizer Grant 45130: LOI Pneumococcal Disease Prevention Grant ID: 45130
More informationis to improve the future
Autism Speaks Suzanne and Bob Wright Trailblazer Award Program 2013 Request for Applications Autism Speaks places a high priority on innovation and has designed its new Trailblazer Award to respond quickly
More informationCancer Care Ontario / Ontario Public Drug Programs
Cancer Care Ontario / Ontario Public Drug Programs Policy: Public funding of cancer drugs and their administration within the context of clinical trials Version: 3.0 Effective Date: December 12, 2016 Replaces
More informationDRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
More informationPLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.
PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to July 1, 2012. It is intended for information and reference purposes only. This
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationPfizer Medical Education Group Request for Proposals (RFP) Rheumatoid Arthritis Appropriate Immunizations in RA Patients
Pfizer Medical Education Group Request for Proposals (RFP) Rheumatoid Arthritis Appropriate Immunizations in RA Patients I. Background The mission of the Pfizer Medical Education Group is to accelerate
More information2016 Grant Application Form
2016 Grant Application Form OUR MISSION: The Border AIDS Partnership is committed to securing sustainable resources, and mobilizing community services to provide funding to organizations that offer education,
More informationTobacco Prevention, Education & Cessation Grant Program. Tobacco Cessation Awareness Campaign and Web Hub
Tobacco Prevention, Education & Cessation Grant Program Tobacco Cessation Awareness Campaign and Web Hub Request for Proposal #: SF-PSD13090412 CAMPAIGN I. Background, Overview and Goals The mission of
More informationCall for Applications
2013 Knowledge Synthesis Grant Program Call for Applications Program Guidelines Overview Technology Evaluation in the Elderly Network (TVN or the Network) is a new network funded by the Government of Canada
More informationCOMMUNITY FUNDRAISING TOOLKIT
COMMUNITY FUNDRAISING TOOLKIT WELCOME AND THANK YOU Whether you are grateful for the care you or your family has received from Michigan Medicine or you re passionate about curing a disease that has affected
More informationLondon Regional Cancer Program
London Regional Cancer Program Table of Contents Mission, Vision and Values...1 Key Areas and Directions... 2 Leading in Patient Care and Service Delivery... 2 Improving Quality and Safety... 5 Strengthening
More informationUC Brain Tumor Center Molecular Therapeutics Pilot Grant Program 2013/2014
Introduction An estimated 25,000 new cases of primary brain tumors will be diagnosed in the United States in 2013, and an estimated 170,000 patients will be diagnosed with brain metastases, most often
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018
pan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationKansas Department of Health and Environment (KDHE) Kansas Data-Driven Prevention Initiative Request for Proposal (RFP) Fiscal Year 2019
Kansas Department of Health and Environment (KDHE) Kansas Data-Driven Prevention Initiative Request for Proposal (RFP) Fiscal Year 2019 Kansas Department of Health and Environment Bureau of Health Promotion
More informationPHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS
PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS For Producer Audience Only - Please Do Not Distribute Regence has selected Prime Therapeutics as the Pharmacy benefits manager for its health plans.
More informationpan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017
pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017 DISCLAIMER Not a Substitute for Professional Advice This report
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kadcyla) Reference Number: CP.PHAR.229 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See
More informationComprehensive Cancer Control Technical Assistance Training and Communication Plan. PI: Mandi Pratt-Chapman, MA. Cooperative Agreement #1U38DP
Comprehensive Cancer Control Technical Assistance Training and Communication Plan PI: Mandi Pratt-Chapman, MA Cooperative Agreement #1U38DP004972-01 July 2014 Acknowledgement: This work was supported by
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationCommunity Advisory Council Application
Monterey Bay Community Power Community Advisory Council Application Monterey Bay Community Power (MBCP) seeks qualified, passionate and committed applicants for its volunteer Community Advisory Council
More informationRe Advertised TERMS OF REFERENCE NATIONAL INDIVIDUAL CONSULTANT - HIV AND AIDS, HUMAN RIGHTS AND THE LAW
Re Advertised TERMS OF REFERENCE NATIONAL INDIVIDUAL CONSULTANT - HIV AND AIDS, HUMAN RIGHTS AND THE LAW Title of Post: HIV, Human Rights and Law Consultant Location: Nairobi, Kenya Type of contract: Individual
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationTHE MICHAEL J. FOX FOUNDATION FOR PARKINSON S RESEARCH. Funding Opportunities
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON S RESEARCH Funding Opportunities AGENDA 1. Brief Overview of MJFF Philosophy 2. MJFF Funding Programs 3. How to apply 4. What happens next? 5. Q&A Please feel
More informationOne Breast Cancer Annual Report
One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the
More informationAustralian Sonographer Accreditation Registry (ASAR) Policy & Procedure 9 - Annual Reporting Requirements for Accredited Sonography Courses
Sonography 1. Preamble ASAR s objective is to promote high standards of medical sonography in Australia which includes setting uniform, minimum standards of sonographer education by assessing and accrediting
More informationINDUSTRY SATELLITE SYMPOSIUM THORACIC CANCERS. Application Deadline: December 16,
M U LT I D I S C I P L I N A R Y THORACIC CANCERS S Y M P O S I U M B R I N G I N G P R E C I S I O N M E D I C I N E TO T H O R A C I C C A N C E R C A R E SAN F R ANCI SCO MAR R I OT T MA RQUIS San Francisco
More informationLCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH 2017 REQUEST FOR APPLICATION (RFA)
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2017 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
More informationVia Electronic Submission. March 13, 2017
APTQI 20 F Street, NW Suite #700 Washington, DC 20001 Phone: 202-507-6354 www.aptqi.com Via Electronic Submission Centers for Medicare & Medicaid Services Department of Health & Human Services Attention:
More information2015 Call for Poster Presentations
2015 Call for Poster Presentations Overview We cordially invite you to submit a proposal to present a Poster Presentation at the 2015 Annual Conference for NAADAC, the Association for Addiction Professionals.
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018
pan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationWELLPOINT RESPONDS TO ANCO s COMMENTS
WELLPOINT RESPONDS TO ANCO s COMMENTS Thank you again for taking the time to meet with us to learn about Anthem s Cancer Care Quality Program and the Wellpoint Cancer Treatment Pathways as well as your
More informationTOBACCO CONTROL PROGRAM COMMUNITY GRANT. REQUEST FOR PROPOSALS- Release Date: October 2, 2018 Application Deadline: October 19, 2018 at 5:00 PM
TOBACCO CONTROL PROGRAM COMMUNITY GRANT REQUEST FOR PROPOSALS- Release Date: October 2, 2018 Application Deadline: October 19, 2018 at 5:00 PM PURPOSE Build capacity of Alameda County residents to participate
More informationNEW THIS YEAR! Submit a session proposal by September 2, 2014! CALL FOR SESSION PROPOSALS
NEW THIS YEAR! Submit a session proposal by September 2, 2014! CALL FOR SESSION PROPOSALS Talking Stick Resort Scottsdale, Arizona February 20-22, 2015 INTRODUCTION The American Academy of Sleep Medicine
More informationPaediatric and Adolescent HIV Research Grant Programme
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Paediatric and Adolescent HIV Research Grant Programme Call for Letter of Intent Table of Contents I. GRANT INFORMATION... 2
More informationDrug Prior Authorization Form Opdivo (nivolumab)
This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required
More informationAdvocacy Framework. St. Michael s Hospital Academic Family Health Team
Advocacy Framework St. Michael s Hospital Academic Family Health Team Purpose To provide a framework by which the St. Michael s Hospital Academic Family Health Team (SMH AFHT) can expand its commitment
More informationEnvironmental, Health and Safety
Environmental, Health and Safety Codes of Practice The Environmental, Health and Safety (EHS) Codes of Practice set forth Zimmer EHS requirements for our business functions and facilities worldwide. In
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 29 Mar 2017 1 of 8 Surname Forename DOB Gender Histology # Primary site Tumour subtype Tissue Type
More informationAdvances in the Multidisciplinary Management of Hepatocellular Carcinoma: Strategies for Incorporating Emerging Immunotherapy Treatment Options
Advances in the Multidisciplinary Management of Hepatocellular Carcinoma: Strategies for Incorporating Emerging Immunotherapy Treatment Options Interim Outcomes Report Merck & Co., Inc. Grant ID: AAN-170919-044712
More informationFOR SHORETEL CHANNEL PARTNERS ShoreTel MDF Program ELIGIBLE ACTIVITIES
FOR SHORETEL CHANNEL PARTNERS ShoreTel MDF Program ELIGIBLE ACTIVITIES Table of Contents Advertising Billboards, Electronic, Magazines, Newspapers, Trade Journals 2 Demand Generation Services 2 Direct
More informationCommunity Fundraising Toolkit
Community Fundraising Toolkit WELCOME AND THANK YOU Whether you are grateful for the care you or your family has received from the University of Michigan Health System (UMHS) or you re passionate about
More informationRequest for Proposals: Consultancy Evaluation, Toolkits and Economic Impact of the 22nd International AIDS Conference
Request for Proposals: Consultancy Evaluation, Toolkits and Economic Impact of the 22nd International AIDS Conference Proposals will be accepted until Friday 6 April 2018 1. About the International AIDS
More informationPfizer Independent Grants for Learning & Change Track 2- Annual Meetings: Submission Deadlines, Areas of Interest & Educational Goals
In order to submit a request for general meeting support through Track 2- Annual Meetings the answer to the following questions must be Yes : Does the activity align with Pfizer s areas of interest? (listed
More informationNews Release. Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab.
Your Contacts News Release Merck Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160
More informationSTATE OF NEW JERSEY DEPARTMENT OF CORRECTIONS. Medication Assisted Treatment For Substance Use Disorder In the New Jersey County Jails
STATE OF NEW JERSEY DEPARTMENT OF CORRECTIONS Medication Assisted Treatment For Substance Use Disorder In the New Jersey County Jails NOTICE OF GRANT OPPORTUNITY (Updated) Announcement Date: September
More informationCannabis Retail Store Licensing in Ontario. General Committee December 10, 2018
1 Cannabis Retail Store Licensing in Ontario General Committee December 10, 2018 Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 Item 12 Presentation Outline Federal Regulatory
More informationREQUEST FOR PROPOSAL Product opportunity assessment for the development of vaccines against pathogens with high levels of antimicrobial resistance
REQUEST FOR PROPOSAL Product opportunity assessment for the development of vaccines against pathogens with high levels of antimicrobial resistance INTRODUCTION The Wellcome Trust is the world s second
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Perjeta) Reference Number: CP.PHAR.227 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationNotification for Outpatient Injectable Chemotherapy for Medicare Advantage Plans Frequently Asked Questions
Notification for Outpatient Injectable Chemotherapy for Medicare Advantage Plans Frequently Asked Questions Key Points Physicians and facilities are required to submit notification to UnitedHealthcare
More informationTriple-Negative Breast Cancer
Triple-Negative Breast Cancer Payal D. Shah, MD Basser Center for BRCA Abramson Cancer Center University of Pennsylvania October 13, 2017 Outline What is triple-negative breast cancer? Treatment updates
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
brentuximab. Given that the median survival of Hodgkin lymphoma patients who relapse after ASCT is approximately two years, perc considered that the manufacturer had substantially overestimated the incremental
More informationREQUEST FOR PROPOSALS FOR CY 2019 FUNDING. Issue Date: Monday, July 30, Submission Deadline: 5:00 p.m., Friday, August 24, 2018
REQUEST FOR PROPOSALS FOR CY 2019 FUNDING Issue Date: Monday, July 30, 2018 Submission Deadline: 5:00 p.m., Friday, August 24, 2018 NOTE: RFP proposals received after the deadline will not be considered.
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationBristol-Myers Squibb Independent Medical Education
Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date 4/19/18 RFE Requestor Information RFE Code Name: Maria Deutsch, MS, PharmD Title: IME Specialist, Oncology
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationTHE REGIONAL MUNICIPALITY OF NIAGARA REQUEST FOR PRE-QUALIFICATION (RFPQ) OF
THE REGIONAL MUNICIPALITY OF NIAGARA REQUEST FOR PRE-QUALIFICATION (RFPQ) OF CESSATION SUPPORT AND NICOTINE REPLACEMENT THERAPY TO RESIDENTS IN THE COMMUNITY DOCUMENT NUMBER# ISSUE DATE: WEDNESDAY OCTOBER
More informationMackenzie Valley Review Board EA Whatì Public Hearing. November 15, 2017 (Day 1)
Mackenzie Valley Review Board EA1617-01 Whatì Public Hearing November 15, 2017 (Day 1) Outline Project History & Purpose Project Description Design & Procurement Overview of Environmental Assessment Key
More informationNumber: III-45 Effective Date: 1 February 2012 Revised Date: November 2016
Page 1 of 8 RATIONALE The BCCA Compassionate Access Program (CAP) application process is intended to address the goals of the BCCA Systemic Therapy Treatment Policy Number III-40. It supports flexibility
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
large impact on cost-effectiveness. perc discussed that one of the main factors affecting the costeffectiveness estimates was the survival estimates used in the economic model. In reviewing the clinical
More informationBristol-Myers Squibb Independent Medical Education
Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date August 6, 2018 RFE Requestor Information RFE Code Name: Maria Deutsch, MS, PharmD, RPh Title: IME Specialist,
More informationESMO ACROSS ONCOLOGY. WORLDWIDE. Josep Tabernero. ESMO President. ESMO SUMMIT MIDDLE EAST Friday, 6 th April 2018
ESMO ACROSS ONCOLOGY. WORLDWIDE Josep Tabernero ESMO President ESMO SUMMIT MIDDLE EAST Friday, 6 th April 2018 ESMO IN A NUTSHELL Europe s leading Medical Oncology Society ESMO is the leading European
More informationRequest for Proposals
Request for Proposals Innovative Model for Bringing Autism Expertise and Services to Rural Areas of Pennsylvania The Pennsylvania Department of Public Welfare (DPW) through the Tuscarora Intermediate Unit
More informationAlign your brand with one of education s most highly respected and experienced organizations.
Christian Schools International Sponsorship Opportunities 2014-2015 Align your brand with one of education s most highly respected and experienced organizations. Sponsorship Opportunities Join Us. Founded
More informationThe Financial Value of STTR for Non-Profit Research
The Financial Value of STTR for Non-Profit Research Introduction Minimizing the Direct Labor Overhead Rate as a Metric for Success Greg Evans, Durestec For non-profit research institutions, managing PhD
More informationJuly 22, The Smoking Cessation Initiative Description- A Multi-Prong Approach: 1. RNAO Smoking Cessation (SC) Coordinators
1 Registered Nurses Association of Ontario Smoking Cessation Nursing Best Practice Initiative Request for Proposal: Smoking Cessation Implementation Site 2013-2014 The Registered Nurses Association of
More informationThe Current Landscape of Nurse Navigators: Oncology and the Impact on Outcomes
The Current Landscape of Nurse Navigators: Oncology and the Impact on Outcomes SHERYL RILEY RN, OCN, CMCN DIRECTOR OF CLINICAL SERVICES SAI SYSTEMS SRILEY@SAISYSTEMS.COM 2015 SAI SYSTEMS INTERNATIONAL
More informationNEW PROVIDER ENROLLMENT FOR ADULT SITE
New Jersey Department of Health Vaccines for Children (NJVFC) Program P.O. Box 369 Trenton, NJ 08625-0369 Phone: (609) 826-4862 Fax: (609) 826-4868 INSTRUCTIONS: Email completed New Provider Enrollment
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lartruvo) Reference Number: CP.PHAR.326 Effective Date: 03.01.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important
More informationClinical Policy: Topotecan (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: Last Review Date: Line of Business: Medicaid, HIM
Clinical Policy: (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: 06.01.11 Last Review Date: 05.18 Line of Business: Medicaid, HIM Coding Implications Revision Log See Important Reminder at the
More informationRegulatory Landscape for Precision Medicine
Regulatory Landscape for Precision Medicine Adam C. Berger, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA FOCR-Alexandria A Blueprint for Breakthrough Meeting September 13, 2017 1 What
More informationMinistry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW
Chapter 1 Section 1.08 Ministry of Health and Long-Term Care Palliative Care Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW # of Status of Actions Recommended Actions
More informationProvincial Cancer Control Advisory Committee
Provincial Cancer Control Advisory Committee Annual Performance Report 2012-2013 Table of Contents 1.0 Overview... 4 2.0 Shared Partnerships... 7 3.0 Highlights and Accomplishments... 7 4.0 Report on
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationWebsite Briefing document for Multiple Sclerosis Society of Ireland.
Website Briefing document for Multiple Sclerosis Society of Ireland. Issued By: The Multiple Sclerosis Society of Ireland 80, Northumberland Rd Dublin 4 Tel: 01-678 1604 Email: thomasm@ms-society.ie Tender
More informationGeriatrics / Gerontology Education
2018 Geriatrics / Gerontology Education Call for Proposals Dr. Paula Rochon, RTO/ERO Chair in Geriatric Medicine, with trainees. RTO/ERO Foundation 2018 Grant Criteria & Call for Proposals February 20,
More informationPMICIE 2014 Volunteer Service Positions Contents
2014 Volunteer Service Positions Contents Board of Director Positions... 2 Finance Positions... 3 Finance Director... 3 Registration Desk... 3 Marketing Positions... 5 Marketing Director... 5 Communications
More informationBreast Cancer. allied. Theme: Explore New Discoveries in Breast Cancer: Health Promotion and Awareness. 7 th World Congress on
7 th World Congress on allied academies Breast Cancer November 1-2, 2017 Toronto, Canada Theme: Explore New Discoveries in Breast Cancer: Health Promotion and Awareness Dear Prospective Sponsor/Exhibitor,
More informationBoard of Management Students, Staff & Equalities Committee
Board of Management s, Staff & Equalities Committee Date of Meeting Wednesday 24 October 2018 Paper No. SSEC2-J Agenda Item 13 Subject of Paper FOISA Status Primary Contact Date of production Action British
More informationThursday, April 23. Incorporating ClinicalTrials.gov Into Patient Education and Care Coordination. Session 1:30 3 pm Valencia BC
Session 1:30 3 pm Valencia BC Incorporating ClinicalTrials.gov Into Patient Education and Care Coordination Clinical trials play a significant role in improving cancer treatment, symptom management, and
More informationRFQ:-HPCSA 03/2017 REQUEST FOR QUOTATION FOR OCCUPATIONAL HEALTH SERVICE ON BEHALF OF THE HEALTH PROFESSIONS COUNCIL OF SOUTH AFRICA
RFQ:-HPCSA 03/2017 REQUEST FOR QUOTATION FOR OCCUPATIONAL HEALTH SERVICE ON BEHALF OF THE HEALTH PROFESSIONS COUNCIL OF SOUTH AFRICA Situated at: 553 Madiba Street, Arcadia, Pretoria Deadline for submission:
More informationDecember 4, 2017 VIA ELECTRONIC SUBMISSION
VIA ELECTRONIC SUBMISSION December 4, 2017 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Development of a List of pre-dietary Supplement
More informationWCO Guidelines for the recognition of University Customs Curricula (2018)
WCO Guidelines for the recognition of University Customs Curricula (2018) CONTENTS INTRODUCTION 2 ELIGIBILITY CRITERIA 2 OVERVIEW OF THE APPLICATION PROCESS 2 FORM OF RECOGNITION 4 DURATION AND RENEWAL
More information